Siponimod, terapia orale per le forme recidivanti di sclerosi multipla sviluppato da Novartis, ha ricevuto l’approvazione da parte della Food and Drug statunitense, e sarà quindi disponibile in commercio a breve. Nel caso dell’Unione Europea,…
Il sito Neurologia Italiana è una testata registrata presso il Tribunale di Milano, 111 del 5/10/2020
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.